J&J Subsidiary, Cordis Corporation has seen two-year data from its INNOVATION Trial presented at the 2014 Leipzig Interventional Course (LINC) in Germany. Data from the study continues to demonstrate that the INCRAFT® System performs well in patients suffering from abdominal aortic aneurysms (AAA) two years after treatment.
An estimated 24 million people worldwide suffer from abdominal aortic aneurysms (AAA),most of which, left untreated, would eventually rupture, with life-threatening consequences. In the U.S. alone, approximately 15,000 people die every year due to an AAA rupture. Endovascular aneurysm repair (EVAR) is a minimally invasive alternative to open surgery for the repair of AAAs. The procedure involves the placement of a stent graft into the aneurysm through a small incision in the groin to prevent it from rupturing.
The INCRAFT® System is an endovascular stent graft used in the treatment of AAA featuring an integrated delivery system with an ultra-low profile equivalent to that of a regular 13 French catheter sheath introducer. This ultra-low profile device is designed for proximal and distal placement accuracy and can be customized during the procedure.
The INNOVATION Trial is a multicenter, open-label, prospective study designed to assess the safety and performance of the device in the treatment of patients with AAA with investigational sites in Germany and Italy. Study Investigator Prof. Giovanni Torsello, MD, of the University Hospital Münster in Germany presented the two-year results of the INNOVATION study at LINC. At two years, there were no incidences of aneurysm enlargement, endoleaks (type I, III or IV), device or procedure related major adverse events, stent-graft migrations or stent fractures. One patient in the study developed a late graft occlusion unrelated to the device that was caused by shrinkage of the aneurysm.2
“These positive results are encouraging and build on the favorable short and mid-term outcomes of the INCRAFT® System observed in the recently published one-year results of the INNOVATION Trial,” said Prof. Gioachino Coppi, MD, Department of Vascular Surgery at the University of Modena in Italy. “In light of these results and the unique low-profile configuration of the device, Cordis’ INCRAFT® System has the potential to be a valuable alternative to current devices on the market. The system is designed to offer increased applicability in the broad spectrum of anatomical sizes encountered in patients undergoing endovascular aneurysm repair.”1
“We are very pleased with these excellent longer term results and look forward to making our INCRAFT® System available to clinicians in need of alternative therapeutic options for patients suffering from abdominal aortic aneurysms,” said Celine Martin, Worldwide President, Cordis Corporation. “The INCRAFT® System was designed to address some of the limitations of current AAA stent-grafts and to increase access to this life-saving therapy to a broader range of patients including those with small or diseased vasculature.”
The INCRAFT® System is approved for investigational device use only and it not for sale anywhere in the world.
1 Coppi et al. INCRAFT® Stent-Graft System: one-year outcome of the INNOVATION Trial; J Cardiovasc Surg 2014; 55:51-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24356046
2 Cordis data on file
Source: Cordis Corporation, Business Wire